Eli Lilly is scooping up ATAI for $6.75 per share plus a $2.50 CVR, creating a deeply discounted arbitrage play with potential for a higher bid.
Psychedelics megachurch: Trump EO to fast-track psychedelics is an obvious rip on ATAI